

May 19, 2016
 SymBio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director
 President and Chief Executive Officer
 (Securities Code: 4582)

**Notice concerning the Change of Major and Largest Shareholder
 among the Company's Major Stockholders**

SymBio Pharmaceuticals Limited (Headquarters: Tokyo, "the Company") announced today that the Company's major and largest shareholder among its major stockholders has changed as follows.

1. Date of this change
 May 11, 2016

2. Background to this change

The major and largest shareholder of the Company has changed due to the exercise of stock acquisition rights (the 3rd unsecured bonds with convertible bond type stock acquisition rights) as set out in the large shareholding report submitted by Whiz Partners Inc. as of May 18, 2016 and the borrowing of 3,030,000 shares from Kosei Securities Co., Ltd. pursuant to the related stock lending contract.

3. Overview of the Company's current major and largest shareholder

- (1) Name: Whiz Healthcare Japan 2.0 Investment Limited Partnership
- (2) Address: Atago Green Hills Mori Tower 36F, 2-5-1, Atago, Minato-ku, Tokyo
- (3) Business: Investment Management Business

4. Voting rights and ownership percentage in respect of the Company before and after said change of the major and largest shareholder

	Number of voting rights (number of shares owned)	Ownership percentage in proportion to the total number of voting rights	Order of large shareholders
Before said change (as of May 10, 2016)	—	—	—
After said change	43,105 units (4,310,501 shares)	11.56%	The largest

(Notes)

1. The number of shares excluded from the number of the Company's outstanding shares due to the non-existence of voting rights: 75 shares
 2. The number of the Company's outstanding shares after the exercise of stock acquisition rights as of May 11, 2016: 37,289,124 shares.
 3. The ownership percentage in proportion to the total number of voting rights is rounded off to the second decimal place.
5. Future outlook
- The change of the major and largest shareholder of the Company will not impact the Company's performance or business relationship with other companies.

[Contact]

Investor Relations
Tel: +81(0)3 5472 1125